Clinical Trial Update: Avelumab in Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma[AVENT STUDY] [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for avelumab in relapsed or refractory extranodal NK/T-cell lymphoma (ENKTL).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma Extranodal Nk-t-cell

Drugs mentioned

• Avelumab (avelumab)

Snippet

Sponsor: Samsung Medical Center | Conditions: Lymphoma, Extranodal NK-T-Cell | Phase 2 | Status: UNKNOWN